IPCA Laboratories Ltd
NSE:IPCALAB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 058.6
1 703.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IPCALAB stock under the Base Case scenario is 1 210.96 INR. Compared to the current market price of 1 591.35 INR, IPCA Laboratories Ltd is Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
IPCA Laboratories Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IPCALAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
IPCA Laboratories Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
IPCA Laboratories Ltd
Balance Sheet Decomposition
IPCA Laboratories Ltd
Current Assets | 55.4B |
Cash & Short-Term Investments | 7.1B |
Receivables | 19.3B |
Other Current Assets | 29.1B |
Non-Current Assets | 55.6B |
Long-Term Investments | 3B |
PP&E | 46.6B |
Intangibles | 2.3B |
Other Non-Current Assets | 3.6B |
Current Liabilities | 23.6B |
Accounts Payable | 7.8B |
Accrued Liabilities | 949.4m |
Short-Term Debt | 5.6B |
Other Current Liabilities | 9.3B |
Non-Current Liabilities | 24.1B |
Long-Term Debt | 6.2B |
Other Non-Current Liabilities | 17.9B |
Earnings Waterfall
IPCA Laboratories Ltd
Revenue
|
82.1B
INR
|
Cost of Revenue
|
-27B
INR
|
Gross Profit
|
55.1B
INR
|
Operating Expenses
|
-44.9B
INR
|
Operating Income
|
10.2B
INR
|
Other Expenses
|
-4.4B
INR
|
Net Income
|
5.8B
INR
|
Free Cash Flow Analysis
IPCA Laboratories Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY '25, Ipca Laboratories achieved an impressive 14% growth in its domestic business, significantly outpacing the industry average of 8%. The company also noted a strong 22.89% EBITDA margin, surpassing its earlier guidance of 21%. While the export formulation business saw a 15% increase, API exports faced a 5% decline. The anticipated consolidated revenue growth for the entire year is now projected at 9-10%. Management highlighted successful market share gains, with notable strength in both acute and chronic segments. The focus remains on leveraging synergies from the integration with Unichem to further enhance profitability.
What is Earnings Call?
IPCALAB Profitability Score
Profitability Due Diligence
IPCA Laboratories Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
IPCA Laboratories Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
IPCALAB Solvency Score
Solvency Due Diligence
IPCA Laboratories Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
IPCA Laboratories Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IPCALAB Price Targets Summary
IPCA Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for IPCALAB is 1 555.97 INR with a low forecast of 960.51 INR and a high forecast of 2 026.5 INR.
Dividends
Current shareholder yield for IPCALAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
IPCALAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,155 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 17 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., USA Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one IPCALAB stock under the Base Case scenario is 1 210.96 INR.
Compared to the current market price of 1 591.35 INR, IPCA Laboratories Ltd is Overvalued by 24%.